Impact of cytogenetics on the outcome of adult acute lymphoblastic leukemia: results of Southwest Oncology Group 9400 study
- PMID: 18156492
- PMCID: PMC2254550
- DOI: 10.1182/blood-2007-10-116186
Impact of cytogenetics on the outcome of adult acute lymphoblastic leukemia: results of Southwest Oncology Group 9400 study
Abstract
We examined the prognostic impact of cytogenetics on the outcome of 200 acute lymphoblastic leukemia (ALL) patients 15 to 65 years of age enrolled in Southwest Oncology Group (SWOG)-9400 study. Evaluable cytogenetics or fluorescence in situ hybridization studies were available in 140 (70%) patients. Four karyotype categories (normal [n = 31, 22%], t(9;22)/BCR/ABL1 [n = 36, 26%], other unfavorable [-7, +8, or 11q23 rearrangement, n = 19, 13%], and miscellaneous [n = 54, 39%]) and the biologically and clinically relevant ALL ploidy subgroups were prospectively defined. Overall survival (OS) decreased significantly with increasing age (P = .009) and varied with karyotype category (P < .001). OS was worst for t(9;22)/BCR/ABL1 followed by other unfavorable karyotypes, with hazard ratios (HR) of 3.45 (95% confidence interval [CI], 1.88-6.31) and 2.14 (95% CI, 1.04-4.04), respectively, compared with normal diploid group. OS of the miscellaneous group was similar to that of the normal diploid group (HR = 0.82; 95% CI, 0.44-1.53). Relapse-free survival (RFS) was not significantly associated with age (P = .30) but was heterogeneous among karyotype categories (P < .001) primarily because of poor RFS in t(9;22)/BCR/ABL1 (HR = 3.49; 95% CI, 1.80-6.75) compared with the normal diploid group. After accounting for the variation among karyotype groups, age was not a significant prognostic factor for OS or RFS, highlighting cytogenetics as the most important prognostic factor in adult ALL. This trial was registered at www.ClinicalTrials.gov as #NCT00002665.
Figures
Similar articles
-
Prognostic impact of pretreatment cytogenetics in adult Philadelphia chromosome-negative acute lymphoblastic leukemia in the era of minimal residual disease.Cancer. 2017 Feb 1;123(3):459-467. doi: 10.1002/cncr.30376. Epub 2016 Oct 3. Cancer. 2017. PMID: 27696391 Free PMC article.
-
Prognostic value of karyotypic analysis in children and adults with high-risk acute lymphoblastic leukemia included in the PETHEMA ALL-93 trial.Haematologica. 2002 Feb;87(2):154-66. Haematologica. 2002. PMID: 11836166 Clinical Trial.
-
Structure and significance of cytogenetic abnormalities in adult patients with Ph-negative acute lymphoblastic leukemia.Ter Arkh. 2018 Aug 17;90(7):30-37. doi: 10.26442/terarkh201890730-37. Ter Arkh. 2018. PMID: 30701920
-
The prognostic value of cytogenetics is reinforced by the kind of induction/consolidation therapy in influencing the outcome of acute myeloid leukemia--analysis of 848 patients.Leukemia. 2001 Jun;15(6):903-9. doi: 10.1038/sj.leu.2402142. Leukemia. 2001. PMID: 11417475 Review.
-
Low relapse rate in children with acute lymphoblastic leukemia after risk-directed therapy.J Pediatr Hematol Oncol. 2001 Dec;23(9):591-7. doi: 10.1097/00043426-200112000-00008. J Pediatr Hematol Oncol. 2001. PMID: 11902303 Review.
Cited by
-
The Philadelphia chromosome in leukemogenesis.Chin J Cancer. 2016 May 27;35:48. doi: 10.1186/s40880-016-0108-0. Chin J Cancer. 2016. PMID: 27233483 Free PMC article. Review.
-
Normal Absolute Monocyte Count at the Time of Relapse is Associated with Improved Survival After First Salvage Therapy in Adult Patients with Early Relapsed B-Lineage Acute Lymphoblastic Leukemia.Cancer Manag Res. 2020 Aug 10;12:7097-7105. doi: 10.2147/CMAR.S264194. eCollection 2020. Cancer Manag Res. 2020. PMID: 32848464 Free PMC article.
-
Effect of transplant status in CD19-targeted CAR T-cell therapy: a systematic review and meta-analysis.Med Oncol. 2018 Sep 11;35(11):144. doi: 10.1007/s12032-018-1204-6. Med Oncol. 2018. PMID: 30206753
-
Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022.Bone Marrow Transplant. 2022 Aug;57(8):1217-1239. doi: 10.1038/s41409-022-01691-w. Epub 2022 May 19. Bone Marrow Transplant. 2022. PMID: 35589997 Free PMC article.
-
Is hyperdiploidy a favorable cytogenetics in adults with B-lymphoblastic leukemia?Cancer Med. 2019 Aug;8(9):4093-4099. doi: 10.1002/cam4.2255. Epub 2019 Jun 7. Cancer Med. 2019. PMID: 31173486 Free PMC article.
References
-
- Pui C-H, Relling MV, Downing JR. Acute lymphoblastic leukemia. N Engl J Med. 2004;350:1535–1548. - PubMed
-
- Schrappe M, Reiter A, Ludwig WD, et al. Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90. Blood. 2000;95:3310–3322. - PubMed
-
- Kantarjian HM, O'Brien S, Smith TL, et al. Results of treatment with hyper-CVAD, a dose-intensive regimen in adult acute lymphocytic leukemia. J Clin Oncol. 2000;18:547–561. - PubMed
-
- Faderl S, Jeha S, Kantarjian HM. The biology and therapy of adult acute lymphoblastic leukemia. Cancer. 2003;98:1337–1354. - PubMed
-
- Mitelman F, editor. An Interna-tional System for Human Cytogenetic Nomenclature. Basel, Switzerland: Karger; International System for Human Cytogenetic Nomenclature. p. 1995.
Publication types
MeSH terms
Substances
Associated data
Grants and funding
- CA 35176/CA/NCI NIH HHS/United States
- N01 CA004919/CA/NCI NIH HHS/United States
- CA 63844/CA/NCI NIH HHS/United States
- CA 74647/CA/NCI NIH HHS/United States
- CA 38926/CA/NCI NIH HHS/United States
- N01 CA035176/CA/NCI NIH HHS/United States
- CA 20319/CA/NCI NIH HHS/United States
- U10 CA004919/CA/NCI NIH HHS/United States
- N01 CA035431/CA/NCI NIH HHS/United States
- U10 CA063845/CA/NCI NIH HHS/United States
- N01 CA032102/CA/NCI NIH HHS/United States
- U10 CA035192/CA/NCI NIH HHS/United States
- CA 35119/CA/NCI NIH HHS/United States
- CA 33572/CA/NCI NIH HHS/United States
- CA 52654/CA/NCI NIH HHS/United States
- U10 CA014028/CA/NCI NIH HHS/United States
- N01 CA035119/CA/NCI NIH HHS/United States
- CA 46441/CA/NCI NIH HHS/United States
- N01 CA046441/CA/NCI NIH HHS/United States
- CA 63845/CA/NCI NIH HHS/United States
- U10 CA074647/CA/NCI NIH HHS/United States
- CA 46368/CA/NCI NIH HHS/United States
- CA 35178/CA/NCI NIH HHS/United States
- CA 04919/CA/NCI NIH HHS/United States
- CA 35090/CA/NCI NIH HHS/United States
- N01 CA063844/CA/NCI NIH HHS/United States
- U10 CA035261/CA/NCI NIH HHS/United States
- U10 CA035178/CA/NCI NIH HHS/United States
- CA 35431/CA/NCI NIH HHS/United States
- CA 35192/CA/NCI NIH HHS/United States
- U10 CA045450/CA/NCI NIH HHS/United States
- U10 CA032102/CA/NCI NIH HHS/United States
- U10 CA046282/CA/NCI NIH HHS/United States
- CA 32102/CA/NCI NIH HHS/United States
- N01 CA035178/CA/NCI NIH HHS/United States
- N01 CA038926/CA/NCI NIH HHS/United States
- U10 CA067575/CA/NCI NIH HHS/United States
- U10 CA046441/CA/NCI NIH HHS/United States
- U10 CA045377/CA/NCI NIH HHS/United States
- U10 CA058882/CA/NCI NIH HHS/United States
- CA 67575/CA/NCI NIH HHS/United States
- U10 CA020319/CA/NCI NIH HHS/United States
- U10 CA038926/CA/NCI NIH HHS/United States
- U10 CA042777/CA/NCI NIH HHS/United States
- P30 CA033572/CA/NCI NIH HHS/United States
- U10 CA035431/CA/NCI NIH HHS/United States
- U10 CA035119/CA/NCI NIH HHS/United States
- U10 CA046368/CA/NCI NIH HHS/United States
- CA 45450/CA/NCI NIH HHS/United States
- N01 CA067575/CA/NCI NIH HHS/United States
- CA 42777/CA/NCI NIH HHS/United States
- U10 CA052654/CA/NCI NIH HHS/United States
- CA 58882/CA/NCI NIH HHS/United States
- CA 30206/CA/NCI NIH HHS/United States
- U10 CA035176/CA/NCI NIH HHS/United States
- P01 CA030206/CA/NCI NIH HHS/United States
- U10 CA035090/CA/NCI NIH HHS/United States
- CA 14028/CA/NCI NIH HHS/United States
- U10 CA063844/CA/NCI NIH HHS/United States
- CA 45377/CA/NCI NIH HHS/United States
- CA 35261/CA/NCI NIH HHS/United States
- CA 46282/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Miscellaneous